Table 2 Atherogenic profile of study subjects

Age (years)

49 [45–54]

50 [37–55]

43 [37–47] ^b

0.002

0.001

BMI (kg/m²)

26.4 [24.2–28.7] ^a

28.7 [25.9–31.1]

28.9 [26.1–32.1]

0.008

0.813

Waist (cm)

90 [84–98] ^a

94 [88–104]

96 [88–100]

0.004

0.800

Leptin (μg/L)

5.6 [2.3–13.6]

8.7 [7.2–28]

5.7 [2.6–8.7]

< 0.001

< 0.001

Adiponectin (μg/L)

11.4 [8.8–14.6] ^a

6.8 [4.3–10.4]

5.9 [4.5–8.4]

< 0.001

0.146

Apo B (mg/dL)

103 [86–114]

110 [109–117]

91.8 [82–97.6]

< 0.001

< 0.001

Apo A-II (mg/dL)

1894 [996–2858]

426.5 [401.4–456.5]

702 [497–1062]

< 0.001

< 0.001

Apo C-III (mg/dL)

10.7 [7.3–13.4]

30.68 [24.5–38]

22.8 [13.6–37]

< 0.001

0.231

ANGPTL3 (ng/mL)

9 [6.6–11.2]

18.8 [13.6–22]

108 [10.8–372]

< 0.001

< 0.001

ANGPTL4 (ng/mL)

50.5 [21.5–145.9]

180.9 [151.9–225.3]

384 [239–483]

< 0.001

< 0.001

FGF-19 (pg/mL)

15 [10–81]

15 [7–18]

77 [10–156] ^b

0.052

0.071

FGF-21 (pg/mL)

55.5 [32–89]

12.5 [2–22]

168 [66–316]

< 0.001

< 0.001

FGF-23 (pg/mL)

25 [18–38]

17.5 [16–22]

33[22–50]

0.127

0.417

FABP1 (ng/mL)

37 [2.15–302.1] ^a

15.5 [13.6–20.8]

13 [1–45]

0.010

0.056